

# **Evaluation Report for Category L, Subcategory 1.1 Application**

**Application Number:** 2022-3872

**Application:** Application Subject to Protection of Proprietary Interests in

Pesticide Data (PPIP) Policy – Equivalency/Data Compensation

Assessment

**Product:** Sharda Saflufenacil Technical

**Registration Number:** 35150 **Active ingredient (a.i.):** Saflufenacil **PMRA Document Number:** 3560556

## **Purpose of Application**

The purpose of this application was to register the technical product, Sharda Saflufenacil Technical, based on a registered precedent product.

#### **Chemistry Assessment**

Common Name: Saflufenacil

IUPAC\* Chemical Name: 2-chloro-4-fluoro-*N*-[isopropyl(methyl)sulfamoyl]-5-[3-methyl-

2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2*H*)-

yl]benzamide

CAS† Chemical Name: 2-chloro-5-[3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)-

1(2*H*)-pyrimidinyl]-4-fluoro-*N*-[[methyl(1-methylethyl)amino]sulfonyl]benzamide

Sharda Saflufenacil Technical has the following properties:

Property	Result
Colour and physical state	Off-white solid
Nominal concentration	98.26%
Odour	Odourless
Density	1.52–1.62 g/mL at 20°C
Vapour pressure	$4.5 \times 10^{-12}$ mPa at $20^{\circ}$ C
рН	6.84 (1% w/v) at 20°C



<sup>\*</sup> International Union of Pure and Applied Chemistry

<sup>†</sup> Chemical Abstracts Service

Property	Result
Solubility in water	pH Solubility (g/L)
	4 (buffer) 0.0167
	7 (buffer) 1.1015
	double distilled 0.0275
n-Octanol/water partition coefficient	pH log K <sub>ow</sub>
	4.0 (buffer) 2.26
	7.0 (buffer) 1.61
	double distilled 1.67

The required chemistry data for Sharda Saflufenacil Technical have been provided, reviewed, and found to be acceptable.

## Health, Environmental and Value Assessments

Health, environmental and value assessments were not required for this application.

### Conclusion

The Pest Management Regulatory Agency has completed an assessment of the information provided and has found the information acceptable to register Sharda Saflufenacil Technical.

### References

PMRA Document	Reference
Number	
3378248	2019, Five Batch Analysis of Saflufenacil Technical (TC), DACO: 2.13.1,2.13.2,2.13.3,2.13.4
3378249	2019, Five Batch Analysis of Saflufenacil TC-[CBI Removed] Test, DACO: 2.13.1,2.13.2,2.13.3,2.13.4
3378251	2022, Determination of Physicochemical Properties of Saflufenacil Technical, DACO: 2.14.1,2.14.10,2.14.12,2.14.15,2.14.2,2.14.3,2.14.4,2.14.6,830.7000
3378252	2021, Stability to Normal and Elevated Temperatures, Metals and Metal Ions and Corrosion Characteristics of Saflufenacil Technical, DACO: 2.14.13,2.14.14
3378254	2021, Stability to Normal and Elevated Temperatures, Metals and Metal Ions and Corrosion Characteristics of Saflufenacil Technical (Amendment No. 1 to Final Report), DACO: 2.14.13,2.14.14
3378256	2021, Stability to Normal and Elevated Temperatures, Metals and Metal Ions and Corrosion Characteristics of Saflufenacil Technical (Study Plan Amendment No. 1), DACO: 2.14.13,2.14.14
3378257	2022, Solubility in Water and Organic Solvents of Saflufenacil Technical, DACO: 2.14.7,2.14.8
3378258	2022, Five Batch Analysis of Saflufenacil Technical, DACO: 2.13.3,2.4
3378537	2022, Determination of Partition Coefficient (n-octanol/water) of Saflufenacil Technical, DACO: 2.14.11
3378538	2022, Determination of Vapour Pressure and Henrys Law Constant of Saflufenacil Technical, DACO: 2.14.9
3495365	2023, Synthesis and Impurity Formation of Saflufenacil Technical Grade, DACO: 2.11,2.11.4,2.13.3,2.13.4 CBI
3546989	2024, Determination of [CBI Removed] in Saflufenacil Technical, DACO: 2.13.1,2.13.2,2.13.3,2.13.4 CBI
3556451	2024, Response to Clarifications for Sub. No. 2022-3872, Sharda Saflufenacil Technical, DACO: 2.13.3 CBI

#### © His Majesty the King in Right of Canada, as represented by the Minister of Health Canada, 2024

All rights reserved. No part of this information (publication or product) may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in a retrieval system, without prior written permission of Health Canada, Ottawa, Ontario K1A 0K9.